Abstract
Increased levels of uric acid are associated with cardiovascular disease and the metabolic syndrome. They may predict clinical outcomes and also the onset of hypertension, though it is less clear that hyperuricaemia can be regarded as an independent risk factor given its clustering with other well-recognised factors. Uric acid may increase as a result of pathophysiological processes such as impaired renal sodium handling but may also contribute to renal and vascular damage, particularly endothelial dysfunction. It is notable that the synthesis of uric acid may be associated with the generation of reactive oxygen species if the enzyme xanthine oxidorectase is converted to the oxidase, as may occur in ischaemia. It has been suggested that uric acid may play a role in the pathogenesis of early-onset hypertension but evidence for this is limited. There is also very limited data to suggest that in some circumstances lowering uric acid can lower blood pressure. In the metabolic syndrome, the presence of elevated uric acid concentrations is closely associated with raised triglyceride levels, for reasons that have not been clearly defined. It remains to be seen whether uric acid could or should be considered a specific therapeutic target in cardiovascular disease and especially in hypertension and if so what should be the optimal pharmacological approach to lowering serum urate levels.
Keywords: Hypertension, urate, uric acid, diuretic, metabolic syndrome, insulin resistance, antioxidant
Current Pharmaceutical Design
Title: Uric Acid and Hypertension
Volume: 11 Issue: 32
Author(s): Michael Schachter
Affiliation:
Keywords: Hypertension, urate, uric acid, diuretic, metabolic syndrome, insulin resistance, antioxidant
Abstract: Increased levels of uric acid are associated with cardiovascular disease and the metabolic syndrome. They may predict clinical outcomes and also the onset of hypertension, though it is less clear that hyperuricaemia can be regarded as an independent risk factor given its clustering with other well-recognised factors. Uric acid may increase as a result of pathophysiological processes such as impaired renal sodium handling but may also contribute to renal and vascular damage, particularly endothelial dysfunction. It is notable that the synthesis of uric acid may be associated with the generation of reactive oxygen species if the enzyme xanthine oxidorectase is converted to the oxidase, as may occur in ischaemia. It has been suggested that uric acid may play a role in the pathogenesis of early-onset hypertension but evidence for this is limited. There is also very limited data to suggest that in some circumstances lowering uric acid can lower blood pressure. In the metabolic syndrome, the presence of elevated uric acid concentrations is closely associated with raised triglyceride levels, for reasons that have not been clearly defined. It remains to be seen whether uric acid could or should be considered a specific therapeutic target in cardiovascular disease and especially in hypertension and if so what should be the optimal pharmacological approach to lowering serum urate levels.
Export Options
About this article
Cite this article as:
Schachter Michael, Uric Acid and Hypertension, Current Pharmaceutical Design 2005; 11 (32) . https://dx.doi.org/10.2174/138161205774913246
DOI https://dx.doi.org/10.2174/138161205774913246 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cigarette Smoking and Hypertension
Current Pharmaceutical Design Non-uremic Calciphylaxis: A Rare and Late Adverse Reaction of Warfarin
Current Drug Safety Hypercoagulability in Sickle Cell Disease and Beta-Thalassemia
Current Molecular Medicine Marinobufagenin in Urine: A Potential Marker of Predisposition to Ethanol and a Target for Spironolactone
Current Hypertension Reviews Impact of Cytochrome P450 2C19*2 and *3 on Clopidogrel Loading Dose in Saudi Patients with Acute Coronary Syndrome
Drug Metabolism Letters Editorial [Hot Topic: Recent Developments in Prodrug Design: Drug Targeting, Pharmacological and Pharmacokinetic Improvements Related to a Reduction of Adverse Effects (Guest Editors: Daniela Melisi & Maria Grazia Rimoli)]
Current Topics in Medicinal Chemistry Heart Failure Modulates the Muscle Reflex
Current Cardiology Reviews Toxicities by Herbal Medicines with Emphasis to Traditional Chinese Medicine
Current Drug Metabolism Selective Serotonin Re-Uptake Inhibitors for the Treatment of Depression in Coronary Artery Disease and Chronic Heart Failure: Evidence for Pleiotropic Effects
Cardiovascular & Hematological Agents in Medicinal Chemistry Safety of Dipeptidyl Peptidase 4 Inhibitors for Treatment of Type 2 Diabetes
Current Drug Safety Strength and Weaknesses of Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease and Possible Detection of Overlaps with Frailty Process
CNS & Neurological Disorders - Drug Targets Urotensin-II Receptor: A Double Identity Receptor Involved in Vasoconstriction and in the Development of Digestive Tract Cancers and other Tumors
Current Cancer Drug Targets Various Presentations of Preeclampsia at Tertiary Care Hospital of Sindh: A Cross-Sectional Study
Current Hypertension Reviews Diacylglycerol Kinases as Emerging Potential Drug Targets for a Variety of Diseases
Current Drug Targets Preface
Current Enzyme Inhibition Current Antioxidant Molecular Therapies for Oxidative Stress-Related Ailments
Current Gene Therapy Sleep and COPD
Current Respiratory Medicine Reviews Telomerase Therapeutics for Degenerative Diseases
Current Molecular Medicine Diversity in Hypertension and Cardiovascular Disease Around the Globe
Current Hypertension Reviews Mannose Binding Lectin: A Potential Biomarker for Many Human Diseases
Current Medicinal Chemistry